. Overview Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (AKI) and GEM-CKD as a treatment for chronic kidney disease (CKD). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California. ...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076552 | EDGAR | 82K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034584 | EDGAR | — |
| 2024-03-22 | 2023-12-31 | 0000950170-24-035322 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-011000 | EDGAR | — |
| 2022-04-15 | 2021-12-31 | 0001213900-22-020179 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001213900-21-019097 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269450 | EDGAR | 18K words |
| 2025-08-08 | 2025-06-30 | 0000950170-25-105284 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066897 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0000950170-24-124036 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094727 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0000950170-24-057787 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062025 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041851 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0000950170-23-023313 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024436 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017405 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009906 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001193125-26-116012 | EDGAR | 1K words |
| 2026-02-26 | 0001193125-26-076833 | EDGAR | — |
| 2026-01-29 | 0001193125-26-027742 | EDGAR | — |
| 2026-01-22 | 0001193125-26-018332 | EDGAR | — |
| 2025-12-03 | 0001193125-25-306915 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269696 | EDGAR | — |
| 2025-10-29 | 0001193125-25-256367 | EDGAR | — |
| 2025-10-15 | 0001193125-25-240400 | EDGAR | — |
| 2025-09-15 | 0001193125-25-203750 | EDGAR | — |
| 2025-09-09 | 0001810560-25-000006 | EDGAR | — |
157 total filings indexed. 129 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001810560 |
| Ticker | REVB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.revbiosciences.com |
| Listed | 2022-01-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report